{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:13:51Z","timestamp":1781835231077,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40256-016-0197-9","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T08:52:38Z","timestamp":1478854358000},"page":"135-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study"],"prefix":"10.1007","volume":"17","author":[{"given":"Jes\u00fas","family":"Mill\u00e1n N\u00fa\u00f1ez-Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Cases Amen\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Ascaso Gimilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivencio","family":"Barrios Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Pascual Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carles","family":"Pedro-Botet Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pint\u00f3 Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto","family":"Serrano Cumplido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"197_CR1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"197_CR2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397\u2013405.","journal-title":"Lancet"},{"key":"197_CR3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","volume":"29","author":"J Shepherd","year":"2006","unstructured":"Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J, Haffner S, et al. Effect of lowering LDL cholesterol substancially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220\u20136.","journal-title":"Diabetes Care"},{"key":"197_CR4","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1001\/archinte.159.22.2661","volume":"159","author":"SM Haffner","year":"1999","unstructured":"Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661\u20137.","journal-title":"Arch Intern Med"},{"key":"197_CR5","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","volume":"98","author":"RB Goldberg","year":"1998","unstructured":"Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al. The Care Investigators: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98:2513\u20139.","journal-title":"Circulation"},{"issue":"10","key":"197_CR6","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","volume":"26","author":"A Keech","year":"2003","unstructured":"Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26(10):2713\u201321.","journal-title":"Diabetes Care"},{"key":"197_CR7","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)12475-0","volume":"361","author":"R Collins","year":"2003","unstructured":"Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005\u201316.","journal-title":"Lancet"},{"key":"197_CR8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358.","journal-title":"Lancet"},{"key":"197_CR9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685\u201396.","journal-title":"Lancet"},{"key":"197_CR10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","volume":"8","author":"BA Golomb","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373\u2013418.","journal-title":"Am J Cardiovasc Drugs"},{"key":"197_CR11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.regg.2012.05.005","volume":"47","author":"X Pinto","year":"2012","unstructured":"Pinto X, Formiga F. Las estatinas, el riesgo de diabetes y el tratamiento de la hipercolesterolemia en la poblaci\u00f3n anciana. Rev Esp Geriatr Gerontol. 2012;47:245\u20136.","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"197_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2012.06.001","volume":"13","author":"N Sattar","year":"2012","unstructured":"Sattar N, Taskinen MR. Statins are diabetogenic. Myth or reality? Atheroscler Suppl. 2012;13:1\u201320.","journal-title":"Atheroscler Suppl"},{"key":"197_CR13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00125-014-3409-3","volume":"57","author":"DI Swerdlow","year":"2014","unstructured":"Swerdlow DI, Sattar N. A dysglycaemic effect of statins in diabetes: relevance to clinical practice? Diabetologia. 2014;57:2433\u20135.","journal-title":"Diabetologia"},{"key":"197_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ebmed-2015-110236","volume":"20","author":"RJ DuBroff","year":"2015","unstructured":"DuBroff RJ. The statin diabetes conundrum: short-term gain, long-term risk or inconvenient truth? Evid Based Med. 2015;20:121.","journal-title":"Evid Based Med"},{"key":"197_CR15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2261-14-85","volume":"14","author":"AF Macedo","year":"2014","unstructured":"Macedo AF, Douglas I, Smeeth L, Forbes H, Ebrahim S. Statins and the risk of type 2 diabetes mellitus: cohort study using de UK clinical practice research datalink. BMC Cardiovasc Disord. 2014;14:85.","journal-title":"BMC Cardiovasc Disord"},{"key":"197_CR16","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","volume":"32","author":"SN Rajpathak","year":"2009","unstructured":"Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924\u20139.","journal-title":"Diabetes Care"},{"key":"197_CR17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735\u201342.","journal-title":"Lancet"},{"key":"197_CR18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, Mac Fadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565\u201371.","journal-title":"Lancet"},{"key":"197_CR19","doi-asserted-by":"crossref","unstructured":"Water DD, Ho JE, Demicco DA, Breazna A, Arsenault BJ, Wun CC et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011; 57: 1535\u201345.","DOI":"10.1016\/j.jacc.2010.10.047"},{"key":"197_CR20","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis. JAMA. 2011;305:2556\u201364.","journal-title":"JAMA."},{"key":"197_CR21","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1136\/bmj.f2610","volume":"346","author":"AA Carter","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patient treated with statins: population based study. BMJ. 2013;346:2610.","journal-title":"BMJ"},{"key":"197_CR22","doi-asserted-by":"crossref","first-page":"g3244","DOI":"10.1136\/bmj.g3244","volume":"348","author":"CR Dormuth","year":"2014","unstructured":"Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, et al. Higher potency statins and the risk of new diabetes: multicenter, observational study of administrative databases. BMJ. 2014;348:g3244.","journal-title":"BMJ"},{"key":"197_CR23","volume-title":"The Delphi method: an experimental study of group opinion","author":"NC Dalkey","year":"1969","unstructured":"Dalkey NC. The Delphi method: an experimental study of group opinion. Santa Monica: Rand Corporation; 1969."},{"key":"197_CR24","volume-title":"The Delphi method, III: use of self ratings to improve group estimates","author":"NC Dalkey","year":"1969","unstructured":"Dalkey NC, Brown B, Cochran S. The Delphi method, III: use of self ratings to improve group estimates. Santa Monica: Rand Corporation; 1969."},{"key":"197_CR25","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","volume":"163","author":"DM Fick","year":"2003","unstructured":"Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults. Results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716\u201324.","journal-title":"Arch Intern Med."},{"key":"197_CR26","unstructured":"Peiro S, Portella E; El grupo nominal en el entorno sanitario. Quaderns de Salut Publica i Administraci\u00f3 de Serveis de Salut 1. Valencia: Escola Valenciana d\u2019Estudis per a la Salut; 2003."},{"key":"197_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7340","volume":"7","author":"P Royle","year":"2003","unstructured":"Royle P, Waugh N. Literature searching for clinical and cost-effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technol Assess. 2003;7:1\u201351.","journal-title":"Health Technol Assess"},{"key":"197_CR28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1214\/aoms\/1177705148","volume":"32","author":"LA Goodman","year":"1961","unstructured":"Goodman LA. Snowball sampling. Ann Math Stat. 1961;32:148\u201370.","journal-title":"Ann Math Stat"},{"key":"197_CR29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.arteri.2015.02.001","volume":"27","author":"J Rius","year":"2015","unstructured":"Rius J, Mill\u00e1n J, Pedro-Botet J, Pint\u00f3 X. La diabetogenicidad de las estatinas: \u00bfson todas iguales? Estado de la cuesti\u00f3n. Clin Invest Arterioscler. 2015;27:148\u201358.","journal-title":"Clin Invest Arterioscler"},{"issue":"2","key":"197_CR30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.atherosclerosis.2015.06.001","volume":"241","author":"AJ Vallejo-Vaz","year":"2015","unstructured":"Vallejo-Vaz AJ, Kondapally SR, Kurogi KM, Michishita I, Nozue T, Sugiyama S, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241(2):409\u201318.","journal-title":"Atherosclerosis"},{"key":"197_CR31","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","volume":"111","author":"EP Navarese","year":"2013","unstructured":"Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111:1123\u201330.","journal-title":"Am J Cardiol"},{"key":"197_CR32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","volume":"172","author":"AL Culver","year":"2012","unstructured":"Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women\u2019s Health Initiative. Arch Intern Med. 2012;172:144\u201352.","journal-title":"Arch Intern Med"},{"key":"197_CR33","first-page":"789","volume":"39","author":"T Teramoto","year":"2011","unstructured":"Teramoto T, Urashima M, Shimano H, Yokote K, Saito Y, LIVES Study Extension Group. A Large-Scale Survey on Cardio-Cerebrovascular Events During Pitavastatin (LIVALO Tablet) Therapy in Japanese Patients with Hypercholesterolemia\u2014LIVALO Effectiveness and Safety Study Extension (LIVES Study Extension). Jpn Pharmacol Ther. 2011;39:789\u2013803.","journal-title":"Jpn Pharmacol Ther"},{"key":"197_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2014.04.001","volume":"15","author":"NA Sattar","year":"2014","unstructured":"Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014;15:1\u201315.","journal-title":"Atheroscler Suppl"},{"key":"197_CR35","doi-asserted-by":"publisher","DOI":"10.2217\/fca-2016-0018","author":"V Barrios","year":"2016","unstructured":"Barrios V, Escobar C. Clinical benefits of pitavastatin: focus on patient with diabetes or at risk of developing diabetes. Future Cardiol. 2016. doi: 10.2217\/fca-2016-0018 .","journal-title":"Future Cardiol"},{"key":"197_CR36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.14423\/SMJ.0000000000000423","volume":"109","author":"JM Backes","year":"2016","unstructured":"Backes JM, Kostoff MD, Gibson CA, Ruisinger JF. Statin-associated diabetes mellitus: review and clinical guide. South Med J. 2016;109:167\u201373.","journal-title":"South Med J"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0197-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0197-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:22:15Z","timestamp":1498360935000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0197-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["197"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0197-9","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}